Article Versions Notes

Lui A, Vanleuven J, Perekopskiy D, Liu D, Xu D, Alzayat O, Elgokhy T, Do T, Gann M, Martin R, et al. FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders. Pharmaceuticals. 2022; 15(12):1546. https://doi.org/10.3390/ph15121546

Lui, Austin, Jordan Vanleuven, David Perekopskiy, Dewey Liu, Desiree Xu, Omar Alzayat, Taiseer Elgokhy, Timothy Do, Meghan Gann, Ryan Martin, and et al. 2022. "FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders" Pharmaceuticals 15, no. 12: 1546. https://doi.org/10.3390/ph15121546

Lui, A., Vanleuven, J., Perekopskiy, D., Liu, D., Xu, D., Alzayat, O., Elgokhy, T., Do, T., Gann, M., Martin, R., & Liu, D. -Z. (2022). FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders. Pharmaceuticals, 15(12), 1546. https://doi.org/10.3390/ph15121546